Finding
In confirmation hearing, FDA nominee Martin Makary talks drug reviews, vaccines, ethics and more
United States Food and Drug Administration, Makary, Vaccines, Ethics, Advisory Committees
Drug Pricing and the Uncertain Future of the IRA Under Trump
IRA, Transplant Registry Unified Management Program, drug price, Medicare, Mediation, repeal, Changing, Uncertainty, Prices
UPDATE: DOGE quietly decreases savings estimate for 30 terminated FDA leases
Financial savings, United States Food and Drug Administration, DOGE, Estimated, leases, terminated – RoleStatus, St. Louis, DOGE ‘s
Freed Raises $30M to Transform Medical Documentation with AI-Powered Assistant
AI medical scribe, clinician burnout, administrative burden, healthcare technology, Series A funding
Lexicon stumbles on second batch of mixed results for pain drug
Dosage, lexicon, Statistical Significance
Australia steadfast on rejection of Eisai, Biogen’s Alzheimer’s therapy Leqembi
Lecanemab, Eisai, Leqembi, Alzheimer ‘s disease, Decision, Presenile dementia, Australia
5 Market Access Mistakes That Can Derail Your EU Orphan Drug Launch
EU, Market, Access, Failed, NR4A2 gene
BioCity’s SC0062 Shows Promise in Phase 2 Trial for Diabetic Kidney Disease
SC0062, endothelin receptor type A (ETA) antagonist, diabetic kidney disease (DKD), proteinuria reduction, phase 2 trial, BioCity Biopharma
Concentra’s Surprise Bid Disrupts Acelyrin-Alumis Merger Plans
Concentra Biosciences, Acelyrin, Alumis, merger disruption, unsolicited offer, biopharmaceutical industry, M&A
Semaglutide Shows Promise in Reducing Alcohol Consumption, Small Study Reveals
semaglutide, Ozempic, Wegovy, alcohol use disorder, GLP-1 drugs, alcohol cravings, weight loss medication, addiction treatment